Table 1 Clinical characteristics of MLCs patients
From: Optimizing the NGS-based discrimination of multiple lung cancers from the perspective of evolution
variables | WES cohort (N = 42) | Non-WES cohort (N = 94) | P value |
|---|---|---|---|
Female | 14 (33.3%) | 55 (58.5%) | 0.009 |
Age (mean ± SD, y) | 65.00 ± 7.77 | 61.90 ± 9.23 | 0.074 |
Pathology | 0.012 | ||
LUAD+Adenosquamous carcinoma | − | 1 (1.1%) | |
LUAD+Large cell neuroendocrine carcinoma | − | 1 (1.1%) | |
LUAD+LUAD | 34 (81.0%) | 85 (90.4%) | |
LUAD+LUAD+LUAD | 4 (9.5%) | − | |
LUAD+LUSC | 1 (2.4%) | 4 (4.3%) | |
LUAD+Poorly differentiated carcinoma | 2 (4.8%) | − | |
LUSC+LUSC | 1 (2.4%) | 3 (3.2%) | |
Stage | 0.339 | ||
IA1 | 1 (2.4%) | 13 (14.6%) | |
IA2 | 12 (28.6%) | 22 (24.7%) | |
IA3 | 9 (21.4%) | 22 (24.7%) | |
IB | 11 (26.2%) | 19 (21.3%) | |
IIA | 2 (4.8%) | 2 (2.2%) | |
IIB | 2 (4.8%) | 5 (5.6%) | |
IIIA | 5 (11.9%) | 6 (6.7%) | |
History of other malignancies | 1 (2.4%) | 9 (9.6%) | 0.174 |
Current or former smoker | 16 (38.1%) | 23 (24.5%) | 0.150 |
Smoking index (mean ± SD) | 341.67 ± 554.45 | 192.55 ± 475.12 | 0.111 |
Synchronous lesions | 38 (90.5%) | 83 (88.3%) | 1.000 |
FEV1 (mean ± SD, L) | 2.43 ± 0.61 | 2.45 ± 0.66 | 0.875 |
DLCO (mean ± SD, %) | 84.12 ± 16.40 | 88.51 ± 14.34 | 0.161 |
Elevated CEA | 11 (26.2%) | −/− | −/− |
Elevated NSE | 6 (14.3%) | −/− | −/− |
Elevated CA199 | 1 (2.4%) | −/− | −/− |
Elevated CA125 | 0 (0.0%) | −/− | −/− |
Recurrence during follow-up | 12 (28.6%) | 15 (16.0%) | 0.105 |
DFS (mean ± SD, m) | 38.39 ± 24.83 | 48.81 ± 30.00 | 0.058 |
Death during follow-up | 6 (14.3%) | 7 (7.4%) | 0.221 |
Follow-up time (mean ± SD, m) | 45.27 ± 25.35 | 53.85 ± 30.50 | 0.155 |
